VAC 072-An Efficacy Study of R21/MM in Different Dose Schedules

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2021

Conditions
Malaria
Interventions
BIOLOGICAL

R21 Matrix-M vaccination

Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly

BIOLOGICAL

R21 Matrix-M vaccination and CHMI

Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite

BIOLOGICAL

R21 Matrix-M vaccination booster

Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule

Trial Locations (4)

SE1 9RT

Guy's and St Thomas' NHS Foundation Trust, London

W2 1NY

Imperial College Healthcare NHS Trust, London

OX3 7LE

CCVTM, University of Oxford, Churchill Hospital, Oxford

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Southampton

All Listed Sponsors
lead

University of Oxford

OTHER

NCT03970993 - VAC 072-An Efficacy Study of R21/MM in Different Dose Schedules | Biotech Hunter | Biotech Hunter